Netflix acquires StoryBots to bring educational content to kids
Category: #headlines  By Mateen Dalal  Date: 2019-05-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Netflix acquires StoryBots to bring educational content to kids

Season 3 of “Ask the StoryBots” would be launched on Netflix in the fall.

The American media services provider Netflix Inc. has reportedly announced that it has acquired StoryBots, children's educational media franchise, to bring educational content to its growing member base of kids and families around the world. The move comes following the launch of highly anticipated rival Disney+.

Reportedly, the acquisition price of the deal is not yet disclosed by Netflix. But as per reliable sources, the price was immaterial to Netflix.

Generally, Netflix does not make acquisitions and prefers to spend directly on content. However, the streaming company rarely acquire content companies. The first acquisition made by Netflix was comic book creator MillarWorld in the year 2017.

“Ask the StoryBots”, a show of StoryBots, was first launched on Netflix in the year 2016. The show features 5 curious creatures who find answers to the questions that kids are often curious about, for example, why we brush our teeth, how night happens.

StoryBots has featured the voices of several celebs to accompany its animated characters, including Edward Norton, Snoop Dogg, Wanda Sykes and Whoopi Goldberg, among others.

Season 3 of “Ask the StoryBots” would be launched on Netflix in the fall.

Under the deal, more StoryBots original programming, including short-form content and additional series, will be produced by the Spiridellis brothers.

The larger goal of Netflix is to own a brand of popular kids’ educational programming – perhaps a Sesame Street for the Netflix era.

Another streaming services, such as Apple TV+ and HBO NOW, have already signed deals with Sesame workshop, the precedent which will have muppets teaching kids programming basics and the latter which now broadcasts Sesame Street.

Gregg and Evan Spiridellis reportedly stated that the company’s goal with Netflix is to make StoryBots the leading educational entertainment brand for families and kids around the world. The opportunity seems to be once-in-a-lifetime chance for the company to bring something epic into the world, he further added.

 

Source credit: https://techcrunch.com/2019/05/09/netflix-acquires-kids-educational-content-co-storybots/

https://media.netflix.com/en/press-releases/netflix-acquires-the-critically-and-fan-acclaimed-storybots-property-and-commits-to-bringing-educational-content-to-kids-and-families-around-the-world

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...